India is shifting its biomedical strategy from high-volume manufacturing to frontier research and development, backed by a ₹1 lakh crore (US $12 billion) innovation fund. By integrating digital public infrastructure, population-scale genetic mapping, and task-specific artificial intelligence, the country aims to establish a "third way" of global health innovation focused on frugal, scalable, and locally adaptable medical solutions.
How India is funding its R&D shift
India’s transition relies on a significant influx of public capital aimed at moving the nation beyond its historical role as a global provider of generic drugs and vaccines. According to the Department of Science and Technology, the government has committed a ₹1 lakh crore Research, Development and Innovation fund to bolster long-term scientific discovery. This financial commitment is complemented by a $1.2 billion allocation specifically for the biopharmaceutical sector. These funds are designed to support the development of 1,000 new clinical trial sites, effectively creating a national network to support multicenter studies that were previously fragmented.
Why population diversity is a research asset
India’s biomedical potential is anchored in its 1.4 billion population, which contains approximately 4,600 endogamous groups. This genetic diversity provides a unique landscape for studying disease-causing mutations that are often absent in Western-centric genetic databases. The GenomeIndia project has already mapped 10,000 genomes, identifying significant variations, including high levels of homozygosity.
These findings are clinically significant, particularly regarding "lean diabetes"—a condition now classified as type 5 diabetes. Research indicates that this subtype, often linked to early-life malnutrition, may not respond to standard type 2 diabetes therapies. As generic GLP-1 medications enter the Indian market, experts warn that relying on Western clinical data could lead to suboptimal patient outcomes.
How digital infrastructure supports health innovation
India is utilizing its digital public infrastructure to bridge the gap between clinical research and real-world application. The Ayushman Bharat Digital Mission has established a framework for health data management, providing digital health IDs to hundreds of millions of citizens. This system allows for the repurposing of existing technology; for instance, the vaccine management platform created during the COVID-19 pandemic is now used for universal childhood immunization programs. This "layer-by-layer" approach ensures that health data is accessible for research while maintaining a foundation for universal healthcare delivery.
Why task-specific AI is replacing general models
Rather than competing with Western tech giants on general-purpose frontier models, India is prioritizing AI tools tailored to its specific linguistic and social constraints. The IndiaAI mission, backed by a $1.25 billion investment, focuses on systems like Sarvam.ai. These voice-first tools provide accessibility for populations with low literacy or those who speak languages underrepresented in standard English-centric chatbots. By designing for real-world usability, India is creating a model of technological adoption that is increasingly being exported to other nations across the Global South through the Centre for Digital Public Infrastructure.
What challenges remain for systemic change
Despite these advancements, India’s research system faces hurdles regarding institutional cohesion and equitable access. According to the Anusandhan National Research Foundation, the primary challenge involves connecting historically isolated universities, hospitals, and biobanks to facilitate large-scale collaboration. Furthermore, while innovation is accelerating, a significant portion of the urban population remains in the "missing middle"—individuals who do not qualify for public health subsidies but cannot afford private care. The success of India’s new biomedical model will ultimately depend on whether these scientific breakthroughs can reach those underserved populations.
Key Takeaways
- Financial Scale: A ₹1 lakh crore fund is supporting the transition from manufacturing to R&D.
- Genetic Insights: The GenomeIndia project is uncovering disease phenotypes, such as type 5 diabetes, that require unique treatment approaches.
- Digital Integration: Health data ecosystems are being repurposed from pandemic management to routine clinical care.
- Strategic Focus: India is building task-specific AI to serve non-English speaking and low-literacy populations.
- Remaining Hurdles: Fragmented institutional collaboration and the "missing middle" in healthcare access remain primary obstacles to widespread impact.
Worth a look